依达拉奉与血栓通联合治疗脑梗死效果分析.docVIP

依达拉奉与血栓通联合治疗脑梗死的效果分析 　　[摘要] 目的 探讨依达拉奉联合血栓通治疗脑梗死的效果。 方法 回顾性分析2014年12月～2015年12月期间来我院进行治疗的137例脑梗死患者的临床资料，按照治疗方法分为两组，研究组68例用依达拉奉联合血栓通治疗；对照组69例单独应用血栓通治疗，比较两组患者的临床疗效、神经功能缺损量表评分、日常生活能力（ADL）。结果 研究组的总有效率（88.2%）与对照组（68.1%）比较明显较高，差异有统计学意义（P0.05）。治疗后两组神经功能缺损量表评分[（9.1±1.4） vs （14.6±2.8）]与治疗前[（19.3±3.5） vs （18.7±3.2）]比较明显降低，ADL评分[（73.7±14.6） vs （61.2±10.5）]与治疗前[（38.6±6.1） vs （39.4±5.7）]比较明显升高，研究组神经功能缺损量表评分降低程度、ADL评分升高的程度与对照组比较更明显，差异有统计学意义（P0.05）。 结论 依达拉奉联合血栓通治疗脑梗死可收到显著疗效，可有效改善患者的神经功能缺失，提高日常生活能力，可在临床推广应用。 　　[关键词] 脑梗死；神经功能；依达拉奉；血栓通 　　[中图分类号] R743.33 [文献标识码] B [文章编号] 1673-9701（2016）10-0041-03 　　[Abstract] Objective To investigate the effect of the cerebral infarction patients treated with edaravone and Xueshuantong. Methods The retrospective analysis included the clinical data of 137 patients with cerebral infarction， all of them were selected from December 2014 to December 2015 in our hospital， they were divided into two groups according to the treatment methods， the study group included 68 patients and were treated with edaravone and Xueshuantong； the control group included 69 cases and were treated with Xueshuantong. The clinical efficacy neurological deficit scale scores， activities of daily living（ADL） of two groups were compared. Results The total effective rate of the study group rate （88.2%） was significantly higher than that of the control group （68.1%）， the difference was statistically significant（P0.05）. After treatment，the neurological deficit scale score of two groups[（9.1±1.4） vs （14.6±2.8）] were significant lower than before treatment[（19.3±3.5） vs （18.7±3.2）]， daily living index score[（73.7±14.6） vs （61.2±10.5）] were increase significantly than before treatment[（38.6±6.1） vs （39.4±5.7）]， the neurological deficit scale score reduced degree， activities of daily living index score elevated degree of the study group were more significant compared with control group， the difference was statistically significant（P0.05）. Conclusion The clinical effect of cerebral infar